VIDEO: One compound improves outcomes in Alzheimer’s, Parkinson’s

SAN DIEGO – One compound from Annovis Bio is showing success in phase 2 clinical trials for both Alzheimer’s disease and Parkinson's disease, a company executive said at the Alzheimer’s Association International Conference.

Annovis founder, CEO and President Maria Maccecchini, PhD, said that Buntanetap (previously known as ANVS401 or posiphen) “either improves cognition in Alzheimer’s or movement in Parkinson’s disease. We are going into phase 3 for Parkinson’s, and for Alzheimer’s we are continuing development in October.”

“I’m proud because this drug will help the afflicted with any neurodegenerative condition and it will actually be a very feasible drug because it’s a neurally available small molecule,” she added.